IDYA
- IDEAYA Biosciences, Inc.
()
Overview
Company Summary
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company that is focused on the discovery and development of targeted therapeutics for oncology. The company utilizes a precision medicine approach to identify and harness genetic and molecular drivers of cancer to effectively treat patients with specific tumor types.
IDEAYA's main objective is to develop potent and selective small molecule drugs that can inhibit the growth and survival of cancer cells. By targeting specific molecular targets that are associated with different types of cancer, the company aims to deliver personalized treatment options that are more effective and less toxic than traditional chemotherapy or radiation therapy.
The company's proprietary drug discovery platform, called Synthetic Lethality Targeted Therapy (SLTT), is a key differentiator. It enables IDEAYA to identify synthetic lethal interactions, which are genetic dependencies in cancer cells that can be exploited using targeted therapies. Synthetic lethal interactions occur when the inhibition of two specific genes is lethal to cancer cells, but not to normal cells. IDEAYA leverages this knowledge to develop innovative drug candidates that can selectively kill cancer cells while sparing healthy tissues.
IDEAYA collaborates with academic institutions, pharmaceutical companies, and other biotechnology firms to advance its drug discovery and development programs. The company's pipeline includes a range of programs, such as targeted therapies for solid tumors and immuno-oncology therapies. IDEAYA employs a rigorous and systematic approach to preclinical and clinical development to ensure the safety and efficacy of its drug candidates.
Overall, IDEAYA Biosciences is dedicated to transforming the treatment landscape for cancer patients by leveraging precise molecular insights and innovative therapies through its SLTT platform.